Multilevel Bayesian Models for Survival Times and Longitudinal Patient-Reported Outcomes With Many Zeros

@inproceedings{Hatfield2012MultilevelBM,
  title={Multilevel Bayesian Models for Survival Times and Longitudinal Patient-Reported Outcomes With Many Zeros},
  author={Laura A. Hatfield and Mark Ernest Boye and Michelle Denise Hackshaw and Bradley P. Carlin},
  year={2012}
}
Regulatory approval of new therapies often depends on demonstrating prolonged survival. Particularly when these survival benefits are modest, consideration of therapeutic benefits to patient-reported outcomes (PROs) may add value to the traditional biomedical clinical trial endpoints. We extend a popular class of joint models for longitudinal and survival data to accommodate the excessive zeros common in PROs, building hierarchical Bayesian models that combine information from longitudinal PRO… CONTINUE READING

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

Bayesian learning in hierarchical joint models,

  • L. Hatfield, J. Hodges, B. Carlin
  • Tech. rep., Division of Biostatistics, School of…
  • 2011
1 Excerpt

Alimta prescribing information,

  • Eli Lilly, Company
  • http://pi.lilly.com/ us/alimta-pi.pdf, Published…
  • 2010
3 Excerpts

FDA will revisit appropriate use of PFS endpoints at advisory committee,

  • M. Laffler
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…